A first-in-human phase Ia dose escalation study of GDC-0077, a p110a-selective and mutant-degrading PI3K inhibitor, in patients with PIK3CA-mutant solid tumors

被引：9

作者：

Juric, Dejan ^{[1
]}

Kalinsky, Kevin ^{[2
]}

Oliveira, Mafalda ^{[3
,4
]}

Cervantes, Andres ^{[5
]}

Bedard, Philippe ^{[6
,7
]}

Krop, Ian ^{[8
]}

Hamilton, Erika ^{[9
]}

Schmid, Peter ^{[10
]}

Varga, Andrea ^{[11
]}

Turner, Nick ^{[12
]}

Italiano, Antoine ^{[13
]}

Saura, Cristina ^{[3
,4
]}

Gambardella, Valentina ^{[5
]}

Veitch, Zachary ^{[6
,7
]}

Dickmann, Leslie ^{[14
]}

Kotani, Naoki ^{[14
]}

Fredrickson, Jill ^{[14
]}

Kapp, Amy ^{[14
]}

Hutchinson, Katie ^{[14
]}

Royer-Joo, Stephanie ^{[14
]}

Vaze, Anjali ^{[14
]}

Schutzman, Jennifer ^{[14
]}

Jhaveri, Komal ^{[15
]}

机构：

[1] Massachusetts Gen Hosp, Boston, MA 02114 USA

[2] Columbia Univ, Irving Med Ctr, New York, NY USA

[3] Vall dHebron Univ Hosp, Barcelona, Spain

[4] Vall dHebron Inst Oncol, Barcelona, Spain

[5] Univ Valencia, Valencia, Spain

[6] Princess Margaret Canc Ctr, Toronto, ON, Canada

[7] Univ Toronto, Toronto, ON, Canada

[8] Dana Farber Canc Inst, Boston, MA 02115 USA

[9] Tennessee Oncol, Sarah Cannon Res Inst, Nashville, TN USA

[10] Queen Mary Univ London, Barts Canc Inst, London, England

[11] Gustave Roussy Canc Campus, Villejuif, France

[12] Inst Canc Res, London, England

[13] Inst Bergonie, Bordeaux, France

[14] Genentech Inc, San Francisco, CA 94080 USA

[15] Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10021 USA

来源：

CANCER RESEARCH | 2020年 / 80卷 / 04期

关键词：

D O I：

10.1158/1538-7445.SABCS19-OT1-08-04

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

OT1-08-04

引用

页数：3

共 50 条

[1] PRECLINICAL DEVELOPMENT OF THE PI3K ALPHA SELECTIVE AND PIK3CA MUTANT SELECTIVE INHIBITOR GDC-0077 AND PREDICTION OF ITS HUMAN PHARMACOKINETICS
Pang, Jodie
Baumgardner, Matthew
Braun, Marie-Gabrielle
Cheong, Jonathan
Edgar, Kyle
Friedman, Lori
Hanan, Emily
Jaochico, Allan
Ma, Shuguang
Plise, Emile
Schmidt, Stephen
Liu, Ning
Song, Kyung
Staben, Steve
Salphati, Laurent
[J]. DRUG METABOLISM AND PHARMACOKINETICS, 2019, 34 (01) : S37 - S37
[2] Discovery of GDC-0077, a highly isoform selective inhibitor of PI3Kα that promotes selective loss of mutant-p110α
Staben, Steven T.
[J]. CANCER RESEARCH, 2017, 77
[3] Discovery of GDC-0077 (Inavolisib), a Highly Selective Inhibitor and Degrader of Mutant PI3Kα
Hanan, Emily J.
Braun, Marie-Gabrielle
Heald, Robert A.
MacLeod, Calum
Chan, Connie
Clausen, Saundra
Edgar, Kyle A.
Eigenbrot, Charles
Elliott, Richard
Endres, Nicholas
Friedman, Lori S.
Gogol, Emily
Gu, Xiao-Hui
Thibodeau, Rebecca Hong
Jackson, Philip S.
Kiefer, James R.
Knight, Jamie D.
Nannini, Michelle
Narukulla, Raman
Pace, Amanda
Pang, Jodie
Purkey, Hans E.
Salphati, Laurent
Sampath, Deepak
Schmidt, Stephen
Sideris, Steve
Song, Kyung
Sujatha-Bhaskar, Swathi
Ultsch, Mark
Wallweber, Heidi
Xin, Jianfeng
Yeap, SiewKuen
Young, Amy
Zhong, Yu
Staben, Steven T.
[J]. JOURNAL OF MEDICINAL CHEMISTRY, 2022, 65 (24) : 16589 - 16621
[4] A phase Ib dose escalation study evaluating the mutant selective PI3K-alpha inhibitor GDC-0077 (G) in combination with letrozole (L) with and without palbociclib (P) in patients with PIK3CA-mutant HR+/HER2-breast cancer
Jhaveri, Komal
Kalinsky, Kevin
Bedard, Philippe
Cervantes, Andres
Saura, Cristina
Krop, Ian
Hamilton, Erika
Schmid, Peter
Varga, Andrea
Turner, Nick
Italiano, Antoine
Gambardella, Valentina
Veitch, Zachary
Oliveira, Mafalda
Dickmann, Leslie
Kotani, Naoki
Kapp, Amy
Hutchinson, Katie
Royer-Joo, Stephanie
Vaze, Anjali
Schutzman, Jennifer
Juric, Dejan
[J]. CANCER RESEARCH, 2020, 80 (04)
[5] GDC-0077 is a selective PI3K alpha inhibitor with robust efficacy in PIK3CA mutant hormone-positive breast cancer models
Edgar, Kyle
Hong, Rebecca
Song, Kyung
Schmidt, Steven
Hafner, Marc
Arrazate, Alfonso
Williams, Erin
De La Cruz, Cecile
Oeh, Jason
Sampath, Deepak
Staben, Steve
Friedman, Lori
[J]. CANCER RESEARCH, 2020, 80 (04)
[6] Phase I Basket Study of Taselisib, an Isoform-Selective PI3K Inhibitor, in Patients with PIK3CA-Mutant Cancers
Jhaveri, Komal
Chang, Matthew T.
Juric, Dejan
Saura, Cristina
Gambardella, Valentina
Melnyk, Anton
Patel, Manish R.
Ribrag, Vincent
Ma, Cynthia X.
Aljumaily, Raid
Bedard, Philippe L.
Sachdev, Jasgit C.
Dunn, Lara
Won, Helen
Bond, John
Jones, Surai
Savage, Heidi M.
Scaltriti, Maurizio
Wilson, Timothy R.
Wei, Michael C.
Hyman, David M.
[J]. CLINICAL CANCER RESEARCH, 2021, 27 (02) : 447 - 459
[7] Discovery of GDC-0077: A highly selective inhibitor of PI3K-alpha that induces degradation of mutant-p110 alpha protein
Braun, Marie-Gabrielle
[J]. ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2018, 256
[8] Discovery of GDC-0077: A highly selective inhibitor of PI3K-alpha that induces degradation of mutant-p110 alpha protein
Braun, Marie-Gabrielle
Chan, Connie
Clausen, Saundra
Edgar, Kyle
Eigenbrot, Charles
Eliott, Richard
Endres, Nick
Friedman, Lori
Gerland, Keira
Gu, Xiao-Hu
Hamilton, Pat
Han, Chong
Hanan, Emily
Hong, Rebecca
Jackson, Philip
Kelly, Sean
Knight, Jamie
Lee, Man-Ling
Lu, Aijun
MacLeod, Calum
McKenzie, Aija
Nannini, Michelle
Narukulla, Raman
Nguyen, Amanda
Pang, Jodie
Purkey, Hans
Salphati, Laurent
Sampath, Deepak
Schmidt, Stephen
Schutt, Leah
Heald, Robert
Song, Kyung
Ultsch, Mark
Xin, Jianfeng
Yeap, Kuen
Young, Amy
Zhong, Zoe
Staben, Steven
[J]. ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2017, 254
[9] First-in-human phase Ia study of the PI3Kα inhibitor CYH33 in patients with solid tumors
Xiao-Li Wei
Fu-Rong Liu
Ji-Hong Liu
Hong-Yun Zhao
Yang Zhang
Zhi-Qiang Wang
Miao-Zhen Qiu
Fei Xu
Qiu-Qiong Yu
Yi-Wu Du
Yan-Xia Shi
De-Sheng Wang
Feng-Hua Wang
Rui-Hua Xu
[J]. Nature Communications, 13
[10] First-in-human phase Ia study of the PI3Kα inhibitor CYH33 in patients with solid tumors
Wei, Xiao-Li
Liu, Fu-Rong
Liu, Ji-Hong
Zhao, Hong-Yun
Zhang, Yang
Wang, Zhi-Qiang
Qiu, Miao-Zhen
Xu, Fei
Yu, Qiu-Qiong
Du, Yi-Wu
Shi, Yan-Xia
Wang, De-Sheng
Wang, Feng-Hua
Xu, Rui-Hua
[J]. NATURE COMMUNICATIONS, 2022, 13 (01)

← 1 2 3 4 5 →